Mayne Pharma Drug Patent Portfolio
Mayne Pharma owns 13 orange book drugs protected by 105 US patents with Doryx having the least patent protection, holding only 2 patents. And Bijuva with maximum patent protection, holding 24 patents. Given below is the list of Mayne Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12233074 | Contraceptive methods with improved pearl index | 09 Feb, 2043 | Active |
| US12257348 | Stabilized microcapsules, method of their preparation and uses thereof | 23 May, 2041 | Active |
| US12133919 | Stabilized microcapsules, method of their preparation and uses thereof | 23 May, 2041 | Active |
| US11628155 | Method for therapeutic treatment of rosacea | 27 Dec, 2040 | Active |
| US12295935 | Method for therapeutic treatment of rosacea | 27 Dec, 2040 | Active |
| US11426378 | Method for long-term treatment of rosacea | 18 Aug, 2040 | Active |
| US10933046 | Method for treatment of rosacea in patients aged 65 years and older | 19 Feb, 2040 | Active |
| US10945987 | Method for providing early onset of action in the treatment of rosacea | 19 Feb, 2040 | Active |
| US11541026 | Method for treatment of rosacea | 19 Feb, 2040 | Active |
| US11865100 | Method for treatment of rosacea in patients aged 65 years and older | 19 Feb, 2040 | Active |
| US11877997 | Method for providing early onset of action in the treatment of rosacea | 19 Feb, 2040 | Active |
| US11986456 | Method for treatment of rosacea | 19 Feb, 2040 | Active |
| US10918649 | System for providing birth control | 21 Jun, 2039 | Active |
| US10925882 | System for providing birth control | 21 Jun, 2039 | Active |
| US10940157 | System for providing birth control | 21 Jun, 2039 | Active |
| US11529308 | System for providing birth control | 21 Jun, 2039 | Active |
| US11850251 | System for providing birth control | 21 Jun, 2039 | Active |
| US10632066 | Method of providing birth control | 01 Feb, 2039 | Active |
| US10765628 | Method of providing birth control | 01 Feb, 2039 | Active |
| US10780047 | Method of providing birth control | 01 Feb, 2039 | Active |
| US10420743 | Methods and compositions for the treatment of acne | 12 Jul, 2038 | Active |
| US10857159 | Halobetasol foam composition and method of use thereof | 30 May, 2037 | Active |
| US10857159 | Halobetasol foam composition and method of use thereof | 30 Nov, 2036 | Active |
| US11020407 | Corticosteroid containing foam compositions and method of manufacture thereof | 30 Nov, 2036 | Active |
| US11793760 | Orodispersible dosage unit containing an estetrol component | 17 Jun, 2036 | Active |
| US11957694 | Orodispersible dosage unit containing an estetrol component | 17 Jun, 2036 | Active |
| US11964055 | Orodispersible dosage unit containing an estetrol component | 17 Jun, 2036 | Active |
| US10335391 | Stabilized oxymetazoline formulations and their uses | 11 Jun, 2035 | Active |
| US10751325 | Stabilized oxymetazoline formulations and their uses | 11 Jun, 2035 | Active |
| US11517560 | Stabilized oxymetazoline formulations and their uses | 11 Jun, 2035 | Active |
| US9974773 | Stabilized oxymetazoline formulations and their uses | 11 Jun, 2035 | Active |
| US9446057 | Controlled release doxycycline | 23 Dec, 2034 | Active |
| US9295652 | Controlled release doxycycline | 23 Oct, 2034 | Active |
| US9511031 | Controlled release doxycycline | 23 Oct, 2034 | Active |
| US11266661 | Vaginal inserted estradiol pharmaceutical compositions and methods | 02 Feb, 2034 | Active |
| US10463740 | Itraconazole compositions and dosage forms, and methods of using the same | 21 Jun, 2033 | Active |
| US10806792 | Itraconazole compositions and dosage forms, and methods of using the same | 21 Jun, 2033 | Active |
| US8921374 | Itraconazole compositions and dosage forms, and methods of using the same | 21 Jun, 2033 | Active |
| US9272046 | Itraconazole compositions and dosage forms, and methods of using the same | 21 Jun, 2033 | Active |
| US9713642 | Itraconazole compositions and dosage forms, and methods of using the same | 21 Jun, 2033 | Active |
| US9687465 | Compositions for the treatment of rosacea | 27 Nov, 2032 | Active |
| US10052386 | Progesterone formulations | 21 Nov, 2032 | Active |
| US10206932 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US10639375 | Progesterone formulations | 21 Nov, 2032 | Active |
| US10675288 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US10806740 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11033626 | Progesterone formulations having a desirable pk profile | 21 Nov, 2032 | Active |
| US11103513 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11103516 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11110099 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11166963 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11529360 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11793819 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US11865179 | Progesterone formulations having a desirable PK profile | 21 Nov, 2032 | Active |
| US8633178 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8846648 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8846649 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8933059 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8987237 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8993548 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US8993549 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US9006222 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US9114145 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US9114146 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US9301920 | Natural combination hormone replacement formulations and therapies | 21 Nov, 2032 | Active |
| US10258630 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10398708 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10471072 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10537581 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10568891 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10668082 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10806697 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10835487 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US10888516 | Soluble estradiol capsule for vaginal insertion | 21 Nov, 2032 | Active |
| US11065197 | Soluble estradiol capsule for vaginal insertion | 21 Nov, 2032 | Active |
| US11116717 | Soluble estradiol capsule for vaginal insertion | 21 Nov, 2032 | Active |
| US11123283 | Soluble estradiol capsule for vaginal insertion | 21 Nov, 2032 | Active |
| US11241445 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US11246875 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US11304959 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US11351182 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US11497709 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US9180091 | Soluble estradiol capsule for vaginal insertion | 21 Nov, 2032 | Active |
| US9289382 | Vaginal inserted estradiol pharmaceutical compositions and methods | 21 Nov, 2032 | Active |
| US12053546 | Stabilized topical formulations containing core-shell microcapsules | 29 Jun, 2032 | Active |
| US8883838 | Pharmaceutical cream compositions and methods of use | 01 Dec, 2031 | Active |
| US10653899 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US11071878 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US12070629 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US10568859 | Topical foam composition | 24 Feb, 2030 | Active |
| US10688071 | Topical foam composition | 24 Feb, 2030 | Active |
| US8808716 | Topical foam composition | 24 Feb, 2030 | Active |
| US9868103 | Metal oxide coating of water insoluble ingredients | 08 Aug, 2028 | Active |
| US8263580 | Vitamin formulation | 07 May, 2028 | Active |
| US7812049 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists | 02 May, 2028 | Active |
| US8715724 | Tabletting process | 03 Feb, 2028 | Active |
| US12156946 | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating | 03 Feb, 2028 | Active |
| US8617580 | Compositions for topical application comprising a peroxide and retinoid | 03 Feb, 2028 | Active |
| US7732430 | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception | 15 Jan, 2028 | Active |
| US8269128 | Vacuum switch tube | 26 May, 2026 | Active |
| US8629128 | Vitamin formulation | 26 May, 2026 | Active |
| US8420688 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists | 02 Aug, 2024 | Expired |
| US8815929 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists | 22 Jan, 2024 | Expired |
| US8771739 | Pharmaceutical compositions for poorly soluble drugs | 25 Jul, 2023 | Expired |
| US6958161 | Modified release coated drug preparation | 15 Dec, 2022 | Expired |
Latest Legal Activities on Mayne Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mayne Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US11123283 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US11116717 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US10537581 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US10537581 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US9289382 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US10806697 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US11497709 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US10806697 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US11266661 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US9289382 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US11266661 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US10668082 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US10668082 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jul, 2024 | US11304959 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 17 Jul, 2024 | US10568891 |
Mayne Pharma's Drug Patent Litigations
Mayne Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 28, 2014, against patent number US10568859. The petitioner , challenged the validity of this patent, with Leon LOUPENOK as the respondent. Click below to track the latest information on how companies are challenging Mayne Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10688071 | February, 2015 |
Decision
(14 Jul, 2017)
| Leon LOUPENOK | |
| US10568859 | April, 2014 |
Decision
(21 Dec, 2016)
| Leon LOUPENOK | |
Mayne Pharma Drug Patents' Oppositions Filed in EPO
Mayne Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 23, 2019, by Rieck, Markus. This opposition was filed on patent number EP13807121A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19163006A | Sep, 2022 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP19163006A | Sep, 2022 | Rieck, Markus | Granted and Under Opposition |
| EP12850845A | Mar, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP12850845A | Mar, 2022 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP12850845A | Mar, 2022 | Rieck, Markus | Granted and Under Opposition |
| EP13807188A | Jan, 2022 | Rieck, Markus | Revoked |
| EP13807121A | Dec, 2019 | Rieck, Markus | Revoked |
Mayne Pharma's Family Patents
Mayne Pharma drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 36.9% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Mayne Pharma Drug List
Given below is the complete list of Mayne Pharma's drugs and the patents protecting them.
1. Annovera
Annovera is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10918649 | System for providing birth control |
21 Jun, 2039
(14 years from now)
| Active |
| US10925882 | System for providing birth control |
21 Jun, 2039
(14 years from now)
| Active |
| US10940157 | System for providing birth control |
21 Jun, 2039
(14 years from now)
| Active |
| US11529308 | System for providing birth control |
21 Jun, 2039
(14 years from now)
| Active |
| US11850251 | System for providing birth control |
21 Jun, 2039
(14 years from now)
| Active |
| US10632066 | Method of providing birth control |
01 Feb, 2039
(13 years from now)
| Active |
| US10765628 | Method of providing birth control |
01 Feb, 2039
(13 years from now)
| Active |
| US10780047 | Method of providing birth control |
01 Feb, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Annovera's drug page
2. Bijuva
Bijuva is protected by 24 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10052386 | Progesterone formulations |
21 Nov, 2032
(7 years from now)
| Active |
| US10206932 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US10639375 | Progesterone formulations |
21 Nov, 2032
(7 years from now)
| Active |
| US10675288 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US10806740 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11033626 | Progesterone formulations having a desirable pk profile |
21 Nov, 2032
(7 years from now)
| Active |
| US11103513 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11103516 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11110099 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11166963 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11529360 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11793819 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US11865179 | Progesterone formulations having a desirable PK profile |
21 Nov, 2032
(7 years from now)
| Active |
| US8633178 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8846648 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8846649 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8933059 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8987237 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8993548 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US8993549 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US9006222 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US9114145 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US9114146 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
| US9301920 | Natural combination hormone replacement formulations and therapies |
21 Nov, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bijuva's drug page
3. Doryx
Doryx is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8715724 | Tabletting process |
03 Feb, 2028
(2 years from now)
| Active |
| US6958161 | Modified release coated drug preparation |
15 Dec, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Doryx's drug page
4. Doryx Mpc
Doryx Mpc is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9446057 | Controlled release doxycycline |
23 Dec, 2034
(9 years from now)
| Active |
| US9295652 | Controlled release doxycycline |
23 Oct, 2034
(9 years from now)
| Active |
| US9511031 | Controlled release doxycycline |
23 Oct, 2034
(9 years from now)
| Active |
| US8715724 | Tabletting process |
03 Feb, 2028
(2 years from now)
| Active |
| US6958161 | Modified release coated drug preparation |
15 Dec, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Doryx Mpc's drug page
5. Epsolay
Epsolay is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12257348 | Stabilized microcapsules, method of their preparation and uses thereof |
23 May, 2041
(15 years from now)
| Active |
| US11628155 | Method for therapeutic treatment of rosacea |
27 Dec, 2040
(15 years from now)
| Active |
| US12295935 | Method for therapeutic treatment of rosacea |
27 Dec, 2040
(15 years from now)
| Active |
| US11426378 | Method for long-term treatment of rosacea |
18 Aug, 2040
(15 years from now)
| Active |
| US10933046 | Method for treatment of rosacea in patients aged 65 years and older |
19 Feb, 2040
(14 years from now)
| Active |
| US10945987 | Method for providing early onset of action in the treatment of rosacea |
19 Feb, 2040
(14 years from now)
| Active |
| US11541026 | Method for treatment of rosacea |
19 Feb, 2040
(14 years from now)
| Active |
| US11865100 | Method for treatment of rosacea in patients aged 65 years and older |
19 Feb, 2040
(14 years from now)
| Active |
| US11877997 | Method for providing early onset of action in the treatment of rosacea |
19 Feb, 2040
(14 years from now)
| Active |
| US11986456 | Method for treatment of rosacea |
19 Feb, 2040
(14 years from now)
| Active |
| US9687465 | Compositions for the treatment of rosacea |
27 Nov, 2032
(7 years from now)
| Active |
| US9868103 | Metal oxide coating of water insoluble ingredients |
08 Aug, 2028
(3 years from now)
| Active |
| US12156946 | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
03 Feb, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epsolay's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Fabior
Fabior is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10568859 | Topical foam composition |
24 Feb, 2030
(4 years from now)
| Active |
| US10688071 | Topical foam composition |
24 Feb, 2030
(4 years from now)
| Active |
| US8808716 | Topical foam composition |
24 Feb, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fabior's drug page
7. Imvexxy
Imvexxy is protected by 20 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11266661 | Vaginal inserted estradiol pharmaceutical compositions and methods |
02 Feb, 2034
(8 years from now)
| Active |
| US10258630 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10398708 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10471072 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10537581 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10568891 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10668082 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10806697 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10835487 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US10888516 | Soluble estradiol capsule for vaginal insertion |
21 Nov, 2032
(7 years from now)
| Active |
| US11065197 | Soluble estradiol capsule for vaginal insertion |
21 Nov, 2032
(7 years from now)
| Active |
| US11116717 | Soluble estradiol capsule for vaginal insertion |
21 Nov, 2032
(7 years from now)
| Active |
| US11123283 | Soluble estradiol capsule for vaginal insertion |
21 Nov, 2032
(7 years from now)
| Active |
| US11241445 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US11246875 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US11304959 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US11351182 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US11497709 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
| US9180091 | Soluble estradiol capsule for vaginal insertion |
21 Nov, 2032
(7 years from now)
| Active |
| US9289382 | Vaginal inserted estradiol pharmaceutical compositions and methods |
21 Nov, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imvexxy's drug page
8. Lexette
Lexette is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10857159
(Pediatric)
| Halobetasol foam composition and method of use thereof |
30 May, 2037
(11 years from now)
| Active |
| US10857159 | Halobetasol foam composition and method of use thereof |
30 Nov, 2036
(11 years from now)
| Active |
| US11020407 | Corticosteroid containing foam compositions and method of manufacture thereof |
30 Nov, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lexette's drug page
9. Nextstellis
Nextstellis is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12233074 | Contraceptive methods with improved pearl index |
09 Feb, 2043
(17 years from now)
| Active |
| US11793760 | Orodispersible dosage unit containing an estetrol component |
17 Jun, 2036
(10 years from now)
| Active |
| US11957694 | Orodispersible dosage unit containing an estetrol component |
17 Jun, 2036
(10 years from now)
| Active |
| US11964055 | Orodispersible dosage unit containing an estetrol component |
17 Jun, 2036
(10 years from now)
| Active |
| US7732430 | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
15 Jan, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nextstellis's drug page
10. Rhofade
Rhofade is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10335391 | Stabilized oxymetazoline formulations and their uses |
11 Jun, 2035
(9 years from now)
| Active |
| US10751325 | Stabilized oxymetazoline formulations and their uses |
11 Jun, 2035
(9 years from now)
| Active |
| US11517560 | Stabilized oxymetazoline formulations and their uses |
11 Jun, 2035
(9 years from now)
| Active |
| US9974773 | Stabilized oxymetazoline formulations and their uses |
11 Jun, 2035
(9 years from now)
| Active |
| US8883838 | Pharmaceutical cream compositions and methods of use |
01 Dec, 2031
(6 years from now)
| Active |
| US7812049 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
02 May, 2028
(2 years from now)
| Active |
| US8420688 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
02 Aug, 2024
(10 months ago)
| Expired |
| US8815929 | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
22 Jan, 2024
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rhofade's drug page
11. Sorilux
Sorilux is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8263580 | Vitamin formulation |
07 May, 2028
(2 years from now)
| Active |
| US8269128 | Vacuum switch tube |
26 May, 2026
(11 months from now)
| Active |
| US8629128 | Vitamin formulation |
26 May, 2026
(11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sorilux's drug page
12. Tolsura
Tolsura is protected by 6 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10463740 | Itraconazole compositions and dosage forms, and methods of using the same |
21 Jun, 2033
(8 years from now)
| Active |
| US10806792 | Itraconazole compositions and dosage forms, and methods of using the same |
21 Jun, 2033
(8 years from now)
| Active |
| US8921374 | Itraconazole compositions and dosage forms, and methods of using the same |
21 Jun, 2033
(8 years from now)
| Active |
| US9272046 | Itraconazole compositions and dosage forms, and methods of using the same |
21 Jun, 2033
(8 years from now)
| Active |
| US9713642 | Itraconazole compositions and dosage forms, and methods of using the same |
21 Jun, 2033
(8 years from now)
| Active |
| US8771739 | Pharmaceutical compositions for poorly soluble drugs |
25 Jul, 2023
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tolsura's drug page
13. Twyneo
Twyneo is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12133919 | Stabilized microcapsules, method of their preparation and uses thereof |
23 May, 2041
(15 years from now)
| Active |
| US12257348 | Stabilized microcapsules, method of their preparation and uses thereof |
23 May, 2041
(15 years from now)
| Active |
| US12295935 | Method for therapeutic treatment of rosacea |
27 Dec, 2040
(15 years from now)
| Active |
| US10420743 | Methods and compositions for the treatment of acne |
12 Jul, 2038
(13 years from now)
| Active |
| US12053546 | Stabilized topical formulations containing core-shell microcapsules |
29 Jun, 2032
(7 years from now)
| Active |
| US10653899 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(5 years from now)
| Active |
| US11071878 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(5 years from now)
| Active |
| US12070629 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(5 years from now)
| Active |
| US9868103 | Metal oxide coating of water insoluble ingredients |
08 Aug, 2028
(3 years from now)
| Active |
| US12156946 | Method for preparing particles comprising metal oxide coating and particles with metal oxide coating |
03 Feb, 2028
(2 years from now)
| Active |
| US8617580 | Compositions for topical application comprising a peroxide and retinoid |
03 Feb, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twyneo's drug page